Episode
Clarifying Cannabis From THCA Loopholes to Schedule III Shifts
- Podcast
- Blunt Business
- Published
- Jun 17, 2026
- Duration seconds
- 2452
- Processing state
not_requested- Canonical source
- https://cannabisradio.com/audio/7919
Actions
POST https://stenobird.com/v1/public/podcasts/blunt-business-326858/episodes/clarifying-cannabis-from-thca-loopholes-to-schedule-iii-shifts/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blunt-business-326858/clarifying-cannabis-from-thca-loopholes-to-schedule-iii-shifts.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Dr. Priyanka Sharma, co-CEO of Kazmira Therapeutics and fellow co-CEO Pulak Sharma, cut through the confusion surrounding the rapidly evolving cannabis and hemp sectors. She clarifies the critical distinction between THCA—the non-intoxicating precursor that converts to THC upon heating—and delta-9 THC, noting that current marketing often masks the potential intoxicating effects of heated THCA products. Dr. Sharma also unpacks the implications of the Schedule III reclassification, explaining why it creates a distinct "two-lane system" for medical cannabis versus industrial hemp rather than a blanket regulatory change. Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy